In Vitro Activity of Miltefosine Against Candida Albicans Under Planktonic and Biofilm Growth Conditions and In Vivo Efficacy in a Murine Model of Oral Candidiasis

Overview

Journal Antimicrob Agents Chemother

Publisher American Society for Microbiology

Specialty Pharmacology

Date 2015 Sep 30

PMID 26416861

Citations 25

Authors

Taissa Vieira Machado Vila

Ashok K Chaturvedi

Sonia Rozental

Jose L Lopez-Ribot

Affiliations

Soon will be listed here.

Abstract

The generation of a new antifungal against Candida albicans biofilms has become a major priority, since biofilm formation by this opportunistic pathogenic fungus is usually associated with an increased resistance to azole antifungal drugs and treatment failures. Miltefosine is an alkyl phospholipid with promising antifungal activity. Here, we report that, when tested under planktonic conditions, miltefosine displays potent in vitro activity against multiple fluconazole-susceptible and -resistant C. albicans clinical isolates, including isolates overexpressing efflux pumps and/or with well-characterized Erg11 mutations. Moreover, miltefosine inhibits C. albicans biofilm formation and displays activity against preformed biofilms. Serial passage experiments confirmed that miltefosine has a reduced potential to elicit resistance, and screening of a library of C. albicans transcription factor mutants provided additional insight into the activity of miltefosine against C. albicans growing under planktonic and biofilm conditions. Finally, we demonstrate the in vivo efficacy of topical treatment with miltefosine in the murine model of oropharyngeal candidiasis. Overall, our results confirm the potential of miltefosine as a promising antifungal drug candidate, in particular for the treatment of azole-resistant and biofilm-associated superficial candidiasis.

Citing Articles

Miltefosine: A Repurposing Drug against Mucorales Pathogens.

Xisto M, Rollin-Pinheiro R, Rochetti V, Castro-Almeida Y, Borba-Santos L, Santos-Freitas G J Fungi (Basel). 2023; 9(12).

PMID: 38132767 PMC: 10744482. DOI: 10.3390/jof9121166.

Therapeutic Potential of Perillaldehyde in Ameliorating Vulvovaginal Candidiasis by Reducing Vaginal Oxidative Stress and Apoptosis.

Chen L, Wang F, Qu S, He X, Zhu Y, Zhou Y Antioxidants (Basel). 2022; 11(2).

PMID: 35204061 PMC: 8868166. DOI: 10.3390/antiox11020178.

A functional genomic screen in Saccharomyces cerevisiae reveals divergent mechanisms of resistance to different alkylphosphocholine chemotherapeutic agents.

Garcia J, Schwabe M, Voelker D, Riekhof W G3 (Bethesda). 2021; 11(10).

PMID: 34568930 PMC: 8496327. DOI: 10.1093/g3journal/jkab233.

Screening of Chemical Libraries for New Antifungal Drugs against Aspergillus fumigatus Reveals Sphingolipids Are Involved in the Mechanism of Action of Miltefosine.

Dos Reis T, Horta M, Colabardini A, Mota Fernandes C, Silva L, Bastos R mBio. 2021; 12(4):e0145821.

PMID: 34372704 PMC: 8406317. DOI: 10.1128/mBio.01458-21.

Miltefosine Against and Species: Antifungal Activity and Its Effects on Fungal Cells.

Rollin-Pinheiro R, Almeida Y, Rochetti V, Xisto M, Borba-Santos L, Rozental S Front Cell Infect Microbiol. 2021; 11:698662.

PMID: 34368017 PMC: 8343104. DOI: 10.3389/fcimb.2021.698662.

References

Mowat E, Lang S, Williams C, McCulloch E, Jones B, Ramage G . Phase-dependent antifungal activity against Aspergillus fumigatus developing multicellular filamentous biofilms. J Antimicrob Chemother. 2008; 62(6):1281-4. DOI: 10.1093/jac/dkn402. View

Sardi J, de Souza Pitangui N, Rodriguez-Arellanes G, Taylor M, Fusco-Almeida A, Mendes-Giannini M . Highlights in pathogenic fungal biofilms. Rev Iberoam Micol. 2013; 31(1):22-9. DOI: 10.1016/j.riam.2013.09.014. View

Samaranayake L . Oral mycoses in HIV infection. Oral Surg Oral Med Oral Pathol. 1992; 73(2):171-80. DOI: 10.1016/0030-4220(92)90191-r. View

Vila T, Ishida K, De Souza W, Prousis K, Calogeropoulou T, Rozental S . Effect of alkylphospholipids on Candida albicans biofilm formation and maturation. J Antimicrob Chemother. 2012; 68(1):113-25. DOI: 10.1093/jac/dks353. View

Martinez L, Casadevall A . Cryptococcus neoformans cells in biofilms are less susceptible than planktonic cells to antimicrobial molecules produced by the innate immune system. Infect Immun. 2006; 74(11):6118-23. PMC: 1695499. DOI: 10.1128/IAI.00995-06. View

Imamura Y, Chandra J, Mukherjee P, Lattif A, Szczotka-Flynn L, Pearlman E . Fusarium and Candida albicans biofilms on soft contact lenses: model development, influence of lens type, and susceptibility to lens care solutions. Antimicrob Agents Chemother. 2007; 52(1):171-82. PMC: 2223913. DOI: 10.1128/AAC.00387-07. View

Calvet H, Yeaman M, Filler S . Reversible fluconazole resistance in Candida albicans: a potential in vitro model. Antimicrob Agents Chemother. 1997; 41(3):535-9. PMC: 163746. DOI: 10.1128/AAC.41.3.535. View

Solis N, Filler S . Mouse model of oropharyngeal candidiasis. Nat Protoc. 2012; 7(4):637-42. PMC: 3671943. DOI: 10.1038/nprot.2012.011. View

Mukherjee P, Chandra J, Yu C, Sun Y, Pearlman E, Ghannoum M . Characterization of fusarium keratitis outbreak isolates: contribution of biofilms to antimicrobial resistance and pathogenesis. Invest Ophthalmol Vis Sci. 2012; 53(8):4450-7. PMC: 3394686. DOI: 10.1167/iovs.12-9848. View

10.

Martinez L, Casadevall A . Susceptibility of Cryptococcus neoformans biofilms to antifungal agents in vitro. Antimicrob Agents Chemother. 2006; 50(3):1021-33. PMC: 1426450. DOI: 10.1128/AAC.50.3.1021-1033.2006. View

11.

Homann O, Dea J, Noble S, Johnson A . A phenotypic profile of the Candida albicans regulatory network. PLoS Genet. 2009; 5(12):e1000783. PMC: 2790342. DOI: 10.1371/journal.pgen.1000783. View

12.

Dorlo T, Balasegaram M, Beijnen J, de Vries P . Miltefosine: a review of its pharmacology and therapeutic efficacy in the treatment of leishmaniasis. J Antimicrob Chemother. 2012; 67(11):2576-97. DOI: 10.1093/jac/dks275. View

13.

Kojic E, Darouiche R . Candida infections of medical devices. Clin Microbiol Rev. 2004; 17(2):255-67. PMC: 387407. DOI: 10.1128/CMR.17.2.255-267.2004. View

14.

Fiori B, Posteraro B, Torelli R, Tumbarello M, Perlin D, Fadda G . In vitro activities of anidulafungin and other antifungal agents against biofilms formed by clinical isolates of different Candida and Aspergillus species. Antimicrob Agents Chemother. 2011; 55(6):3031-5. PMC: 3101406. DOI: 10.1128/AAC.01569-10. View

15.

Ferreira J, Carr J, Starling C, de Resende M, Donlan R . Biofilm formation and effect of caspofungin on biofilm structure of Candida species bloodstream isolates. Antimicrob Agents Chemother. 2009; 53(10):4377-84. PMC: 2764222. DOI: 10.1128/AAC.00316-09. View

16.

Swindell K, Lattif A, Chandra J, Mukherjee P, Ghannoum M . Parenteral lipid emulsion induces germination of Candida albicans and increases biofilm formation on medical catheter surfaces. J Infect Dis. 2009; 200(3):473-80. DOI: 10.1086/600106. View

17.

Montejo M . [Epidemiology of invasive fungal infection in solid organ transplant]. Rev Iberoam Micol. 2011; 28(3):120-3. DOI: 10.1016/j.riam.2011.06.003. View

18.

Seifert K, Matu S, Perez-Victoria F, Castanys S, Gamarro F, Croft S . Characterisation of Leishmania donovani promastigotes resistant to hexadecylphosphocholine (miltefosine). Int J Antimicrob Agents. 2003; 22(4):380-7. DOI: 10.1016/s0924-8579(03)00125-0. View

19.

Wiederhold N, Najvar L, Bocanegra R, Kirkpatrick W, Sorrell T, Patterson T . Limited activity of miltefosine in murine models of cryptococcal meningoencephalitis and disseminated cryptococcosis. Antimicrob Agents Chemother. 2012; 57(2):745-50. PMC: 3553737. DOI: 10.1128/AAC.01624-12. View

20.

Gillum A, Tsay E, Kirsch D . Isolation of the Candida albicans gene for orotidine-5'-phosphate decarboxylase by complementation of S. cerevisiae ura3 and E. coli pyrF mutations. Mol Gen Genet. 1984; 198(2):179-82. DOI: 10.1007/BF00328721. View